Understanding the MASCC Risk Index for Febrile Neutropenia

The MASCC Risk Index is a validated clinical scoring system used to risk-stratify patients with febrile neutropenia (FN) and decide between outpatient vs inpatient management. This tool is very high-yield for FRCPath / ID / Oncology cross-cover and frequently appears in viva scenarios. 👀

🎯 Purpose of the MASCC Risk Index

The MASCC Risk Index helps identify low-risk febrile neutropenia patients who may be safely treated with oral antibiotics ± outpatient care. It was developed by the Multinational Association for Supportive Care in Cancer.

🧾 MASCC Risk Index – Scoring System

Clinical Variable	Score
No or mild symptoms5	5

Maximum score = 26

🔑 Interpretation (EXAM GOLD ⭐)

👉 A score ≥21 has:

• Sensitivity ~70–80%

• High negative predictive value for serious complications

  
  

💊 Typical Low-Risk FN Regimen (UK practice)

If MASCC ≥21 AND clinically stable:

• Oral co-amoxiclav + ciprofloxacin

• Or ciprofloxacin + amoxicillin

• Close follow-up + clear safety-netting

  
  

(Always align with local oncology / antimicrobial FN policy)

⚠️ Important Examiner Caveats

Examiners LOVE these points 👇

• ❌ MASCC does NOT replace clinical judgement

• ❌ Not validated in:

- Acute leukaemia induction

- Stem cell transplant

- Profound/prolonged neutropenia

• Must consider:

- Social support

- Compliance

- Distance from hospital

- Rapid access to care

🗣️ Viva-Style Examiner Question

“A patient with febrile neutropenia has a MASCC score of 22. What would you do?”

Model Answer (Consultant-level):

“A MASCC score ≥21 suggests low-risk febrile neutropenia. If the patient is haemodynamically stable, without organ dysfunction, and has adequate social support, I would consider oral antibiotics with close follow-up, in line with local FN and oncology protocols.”

💎 FRCPath Key Points Summary

• MASCC = risk stratification tool, not a treatment algorithm

• Score ≥21 = low risk

• Enables safe outpatient management in selected patients

• Always combine with clinical judgement + local policy

  
  

❗ MASCC score < 21 — what does it mean?

A MASCC score below 21 = HIGH-RISK febrile neutropenia.

👉 This is NOT a grey zone in the exam.👉 Management is inpatient, IV, and urgent.

🚨 Immediate Implications (Say this in viva)

If MASCC < 21, the patient is at high risk of serious complications, including:

• Sepsis / septic shock

• Organ dysfunction

• ICU admission

• Mortality

Therefore:

Outpatient or oral therapy is inappropriate.

🏥 Management Strategy (Consultant-Level Answer)

1️⃣ Admit to hospital

• Ideally same-day admission

• High-dependency setting if unstable

2️⃣ Immediate IV broad-spectrum antibiotics (within 1 hour)

UK standard first line:

• Piperacillin–tazobactam IV

Alternatives (depending on allergy/local policy):

• Cefepime

• Meropenem (if previous ESBL/CPE risk or septic shock)

⚠️ Do NOT delay antibiotics to calculate scores

3️⃣ Full sepsis work-up

• Blood cultures (peripheral ± line)

• Urine, respiratory samples if indicated

• Lactate, CRP, renal & liver function

• CXR if respiratory symptoms

4️⃣ Risk escalation & supportive care

• IV fluids

• Oxygen

• Early ICU referral if:

  • Hypotension

  • Rising lactate

  • Confusion

  • Respiratory failure

5️⃣ Daily review & de-escalation

• Clinical progress

• Microbiology results

• Step down to oral therapy only after stability

🧠 Examiner Trap (VERY COMMON)

❌ Wrong answer:

“Score is 20 so I’d consider oral antibiotics with close follow-up.”

✅ Correct answer:

“A MASCC score below 21 defines high-risk febrile neutropenia and mandates inpatient IV antibiotic therapy.”

🗣️ Viva One-Liner (Memorise This)

“MASCC <21 equals high-risk febrile neutropenia, requiring hospital admission and immediate IV broad-spectrum antibiotics.”

🔍 Extra Distinction Points (Add if time allows)

• MASCC is validated for identifying low risk, not for downgrading care

• Clinical instability overrides any score

• Consider:

  • Central line infections

  • Fungal infection if persistent fever >4–7 days

  • G-CSF in selected high-risk patients

💎 FRCPath Examiner Takeaway

• ≥21 → consider outpatient

• <21 → inpatient IV treatment

• No exceptions in the exam unless explicitly stated

Get fully trained on Febrile neutropenia and neutropenic sepsis at FRCPathPrep.com Training courses.